Various top quality steroids, semi-finished oils, SARMs, other pharmaceutical raw materials.
Product Details:
Payment & Shipping Terms:
|
| Product Name: | Fulvestrant | Alias: | Faslodex |
|---|---|---|---|
| Appearance: | White Powder | Assay: | 99% |
| Cas: | 129453-61-8 | Usage: | Breast Cancer Treatment |
| High Light: | pharma grade steroids,pharmaceutical anabolic steroids |
||
API Pharmaceutical Raw Materials Fulvestrant Faslodex Breast Cancer Steroids 129453-61-8
Synonyms: Faslodex
CAS:129453-61-8
Molecular Fomular:C32H47F5O3S
Molecular Weight:606.77
Appearance:white powder
Fulvestrant is a highly selective estrogen receptor antagonist. It exerts its action in the body not by
targeting the production of estrogen, but by preventing it from exerting activity on the body. It does this by binding available estrogen receptors in a competitive manner, making them unavailable for circulating
estrogens. This mode of action is very similar to Nolvadex and Clomid, although unlike these two agent
fulvestrant does not have mixed agonist/antagonist properties. It is a pure estrogen receptor antagonist.
This agent also stands out as the first inject able estrogen antagonist to catch the attention of the athletic
and bodybuilding world. Although not widely used here, when applied it may be effective drug for
mitigating the side effects of excess estrogen caused by anabolic/androgenic steroid use such as
gynecomastia, fat buildup, and increased water retention.
Fulvestrant is FDA approved for the treatment of hormone receptor positive metastatic breast cancer in
postmenopausal women with disease progression following anti estrogen therapy. The recommended
dose is 250mg administered intramuscularly per month as a single 5ml injection or two 2.5ml injections.
When used off label to mitigate the estrogenic side effects of anabolic/androgenic steroid use, male
athletes and bodybuilders may find a similar dose as is used for medical reasons to be effective for their
needs.
Quality Test Report(COA):
Test Item |
Specification |
Results |
|
Appearance |
A white to off-white crystalline powder |
White crystalline powder |
|
Identification |
The retention time of the major peak in the chromatogram of the assay preparation is same as that of the standard preparation obtained in the assay |
Conform |
|
Any Individual impurity |
Not more than 0.10% |
0.18% |
|
Total impurities |
Not more than 1.0% |
0.44% |
|
Ratio of isomers |
Fulvestran A |
50.0%-60.0% |
51.70% |
Fulvestran B |
40.0%-50.0% |
47.86% |
|
Purity |
99.0% |
99.56% |
|
Applications:
Fulvestrant Acetate is a selective estrogen receptor degrader (SERD). It is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
Fulvestrant Acetate provides effective second-line therapy in metastatic or locally advanced breast cancer for postmenopausal women who relapse or progress after previous endocrine therapy.
Four clinical trials in this setting showed similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.
A Phase 2 clinical trial, sponsored by Atossa Genetics, is being conducted by Dr. Sheldon Feldman, President of the The American Society of Breast Surgeons, at Columbia University Breast Center in New York City on the use of Fulvestrant Acetate administered through the microcatheter into the lactiferous duct as neoadjuvant treatment forductal carcinoma in situ and invasive breast cancer.
Anti-Estrogens
Femara (Letrozole)
Nolvadex (Tamoxifen Citrate)
Arimidex (Anastrozole)
Aromasin (Exemestane)
Clomid (Clomiphene Citrate)
Fareston (Toremifene Citrate)
Evista (Raloxifene Hydrochloride)
Cytadren (Aminoglutethimide)
Fulvestrant/ Faslodex & Breast Cancer:
Fulvestrant (trade name Faslodex) which was developed by AstraZeneca isan intramuscular injection drug, and it was approved for marketing by the US Food and Drug Administration in April 2002.Fulvestrantis a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. Fulvestrant is used to treat hormone receptor positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods) and whose breast cancer has worsened after they were treated with antiestrogen medications such as tamoxifen (Nolvadex). Fulvestrant is in a class of medications called estrogen receptor antagonists.
Pharmaceutical Raw Material Products:
| Adrafinil | to increases the brain neurotransmitter, hypocretin |
| Aniracetam | to improve learning and memory, increase perception, reduce anxiety and increase reflexes |
| Carphedon |
anti-amnesic, antidepressant,anticonvulsant, antipsychotic, anxiolytic, andmemory enhancement effects |
| Centrophenoxine | shown to improve memory, have a mentally stimulating effect, and improve general cognition for elder patients |
| Coluracetam | potential use in prevention and treatment of ischemicretinopathy and retinaland optic nerve injury and a potential therapeutic drug for schizophrenia |
| IDRA-21 | shown to be valuable in memory improvement, cognitive enhancement, stimulation, and reversing cognitive deficits |
| Modafinil | to improve ability to focus in duration and intensity, analytic capabilities, memory recall and rententio, mood and well-being. |
| Noopept |
to offer many benefits in terms of improving memory, learning capacity, focus, and concentration |
| NSI-189 | to stimulate neurogenesis of human hippocampal stem cells in vitro and in vivo |
| Oxiracetam |
highly effective at increasing attention span, memory, mental energy and cognitive processing |
| PRL-8-53 | to improve learning and memory |
| Sunifiram |
as an ampakine because it gains its effectiveness through the increasing glycine receptor binding |
| Unifiram | to improve learning and memory, increase perception, reduce anxiety and increase reflexes |
| Vinpocetine | shown to be valuable in protecting heart, visual, and hearing functions, among other benefits |
Contact Person: tommy
